Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Butyrate vs Tributyrin: their evidence isn't directly comparable (one is unscored); they work on different things and are often used together, not either/or. Take the 60-second quiz for a pick tailored to your goals.
Butyrate wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Butyrate and Tributyrin have evidence — compare verdict strength side-by-side.
300-600mg sodium/calcium butyrate, 2-3x daily (the one cited trial that states a dose used 600 mg a day)
With meals, Spread throughout day
Enteric-coated sodium or calcium butyrate
500 mg three times daily (1.5 g/day) — the only supplement-realistic dose ever tested in humans, used in the 30-day open-label Parkinson's study. Three times daily is not optional: plasma butyrate is gone by 5 hours after a dose, which is precisely why the second Phase I study abandoned once-daily dosing
Three times daily, spread across the day, Do not consolidate into a single daily dose — plasma butyrate is gone by 5 hours
Plain oral tributyrin, dosed three times daily
Redundant rather than harmful. Critically, the clinical trial record belongs to the SALT, not the prodrug: trials of sodium butyrate in IBS and inflammatory bowel disease are evidence about sodium butyrate. Tributyrin's entire human evidence base is 50 people across three uncontrolled studies, none placebo-controlled and none meeting an efficacy endpoint.
No reason to take both. If you want the compound with human clinical trials behind it, that is sodium butyrate. Tributyrin's case rests on a distal-colonic-delivery claim the evidence does not support — it was rapidly cleaved in the stomach compartment of a validated gut model.
2-4 weeks
4-8 weeks
Within hours
n/a
n/a
n/a
Perturbations in Gut Microbiota Composition in Psychiatric Disorders: A Review and Meta-analysis
JAMA psychiatry (2021) · Meta analysis · n=2948
Umbrella review and meta-analysis of 59 case-control studies comparing the gut microbiota of adults with psychiatric disorders and healthy controls (alpha diversity pooled from 34 studies, 1,519 patients).
Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis
The American journal of clinical nutrition (2018) · Meta analysis · n=2099
Dietary fiber intervention, particularly involving fructans and galacto-oligosaccharides, leads to higher fecal abundance of Bifidobacterium and Lactobacillus spp. but does not affect α-diversity.
Efficacy of a postbiotic and its components in promoting colonic transit and alleviating chronic constipation in humans and mice
Cell reports. Medicine (2025) · Rct · n=110
A randomized, double-blind, placebo-controlled crossover trial involving 110 adults with chronic constipation (Rome IV criteria) demonstrates that a 3-week Probio-Eco intervention significantly improves constipation symptoms, stool straining, and worry scores.
Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement study.
Neurotherapeutics (2026) · Open label · n=17
An open-label study with no placebo group and no blinding. Fourteen people with Parkinson's disease and three healthy controls took 500 mg tributyrin by mouth three times daily for about 30 days. The healthy controls also took tributyrin, they were not a comparison arm.
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug.
Cancer Chemother Pharmacol (2003) · Open label · n=20
20 patients with advanced solid tumours and no other treatment options took tributyrin 150 to 200 mg/kg three times daily, with no control group.
Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
Clin Cancer Res (1998) · Open label · n=13
13 patients with solid tumours took tributyrin at escalating doses of 50 to 400 mg/kg/day, once daily for 3 weeks then 1 week off, with no control group.
Butyrate has gradable evidence while Tributyrin has insufficient evidence to score and wins in 2 of 3 categories.
Redundant rather than harmful. Critically, the clinical trial record belongs to the SALT, not the prodrug: trials of sodium butyrate in IBS and inflammatory bowel disease are evidence about sodium butyrate. Tributyrin's entire human evidence base is 50 people across three uncontrolled studies, none placebo-controlled and none meeting an efficacy endpoint. No reason to take both. If you want the compound with human clinical trials behind it, that is sodium butyrate. Tributyrin's case rests on a distal-colonic-delivery claim the evidence does not support — it was rapidly cleaved in the stomach compartment of a validated gut model. Consult a healthcare provider for personalized advice.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.